Raitakari O T, McCredie R J, Witting P, Griffiths K A, Letters J, Sullivan D, Stocker R, Celermajer D S
Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia.
Free Radic Biol Med. 2000 Apr 1;28(7):1100-5. doi: 10.1016/s0891-5849(00)00201-x.
Oxidative modification of low-density lipoprotein (LDL) may cause arterial endothelial dysfunction in hyperlipidemic subjects. Antioxidants can protect LDL from oxidation and therefore improve endothelial function. Dietary supplementation with coenzyme Q (CoQ(10)) raises its level within LDL, which may subsequently become more resistant to oxidation. Therefore, the aim of this study was to assess whether oral supplementation of CoQ(10) (50 mg three times daily) is effective in reducing ex vivo LDL oxidizability and in improving vascular endothelial function. Twelve nonsmoking healthy adults with hypercholesterolemia (age 34+/-10 years, nine women and three men, total cholesterol 7.4+/-1.1 mmol/l) and endothelial dysfunction (below population mean) at baseline were randomized to receive CoQ(10) or matching placebo in a double-blind crossover study (active/placebo phase 4 weeks, washout 4 weeks). Flow-mediated (FMD, endothelium-dependent) and nitrate-mediated (NMD, smooth muscle-dependent) arterial dilatation were measured by high-resolution ultrasound. CoQ(10) treatment increased plasma CoQ(10) levels from 1.1 +/-0.5 to 5.0+/-2.8 micromol/l (p =.009) but had no significant effect on FMD (4.3+/-2.4 to 5.1+/-3.6 %, p =.99), NMD (21.6+/-6.1 to 20.7+/-7.8 %, p = .38) or serum LDL-cholesterol levels (p = .51). Four subjects were selected randomly for detailed analysis of LDL oxidizability using aqueous peroxyl radicals as the oxidant. In this subgroup, CoQ(10) supplementation significantly increased the time for CoQ(10)H(2) depletion upon oxidant exposure of LDL by 41+/-19 min (p = .04) and decreased the extent of lipid hydroperoxide accumulation after 2 hours by 50+/-37 micromol/l (p =.04). We conclude that dietary supplementation with CoQ(10) decreases ex-vivo LDL oxidizability but has no significant effect on arterial endothelial function in patients with moderate hypercholesterolemia.
低密度脂蛋白(LDL)的氧化修饰可能会导致高脂血症患者的动脉内皮功能障碍。抗氧化剂可以保护LDL不被氧化,从而改善内皮功能。膳食补充辅酶Q(CoQ10)可提高LDL中的辅酶Q水平,随后LDL可能会变得更具抗氧化性。因此,本研究的目的是评估口服补充CoQ10(每日三次,每次50毫克)是否能有效降低离体LDL的氧化能力并改善血管内皮功能。在一项双盲交叉研究(活性/安慰剂阶段4周,洗脱期4周)中,将12名基线时患有高胆固醇血症(年龄34±10岁,9名女性和3名男性,总胆固醇7.4±1.1毫摩尔/升)且存在内皮功能障碍(低于人群平均水平)的非吸烟健康成年人随机分为接受CoQ10或匹配的安慰剂组。通过高分辨率超声测量血流介导的(FMD,内皮依赖性)和硝酸盐介导的(NMD,平滑肌依赖性)动脉扩张。CoQ10治疗使血浆CoQ10水平从1.1±0.5微摩尔/升升高至5.0±2.8微摩尔/升(p = 0.009),但对FMD(4.3±2.4%至5.1±3.6%,p = 0.99)、NMD(21.6±6.1%至20.7±7.8%,p = 0.38)或血清LDL胆固醇水平(p = 0.51)均无显著影响。随机选择4名受试者,以水相过氧自由基作为氧化剂,对LDL的氧化能力进行详细分析。在该亚组中,补充CoQ10可使LDL暴露于氧化剂后CoQ10H2耗尽的时间显著延长41±19分钟(p = 0.04),并使2小时后脂质过氧化氢积累的程度降低50±37微摩尔/升(p = 0.04)。我们得出结论,膳食补充CoQ10可降低离体LDL的氧化能力,但对中度高胆固醇血症患者的动脉内皮功能无显著影响。